ArticleInfluenza and other respiratory viruses2025
Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Evaluation of influenza vaccine effectiveness among older adults in Jiaxing, China, 2022-2025: A test negative design-based study.Human vaccines & immunotherapeutics · 2026Article
- Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study.Journal of global health · 2026Article
- Effectiveness of a trivalent inactivated split-virion influenza vaccine (Tri Fluvac) in Thailand: a phase IV test-negative case-control study.The Lancet regional health. Southeast Asia · 2026Article
- Clinical and Economic Inpatient Burden of Influenza and Influenza-Like Illness in Germany 2019-2025: Analysis of Nationwide Hospital Data.Infectious diseases and therapy · 2026Article
- Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK.Influenza and other respiratory viruses · 2026Article
- Effectiveness of seasonal influenza vaccine against dominant A(H1N1)pdm09 in adults ≥ 60 years: a multicenter test-negative design in Zhejiang, China, 2024-2025.BMC geriatrics · 2026Observational
- Article
- Influenza Vaccine Effectiveness Against Influenza A(H1N1)pdm09-Associated Hospitalizations With SARI in Beijing, China, in the 2024-2025 Season.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1-52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21-88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.